|
Market Cap (5-Jun) $132,782,144 (584th) |
Close (30-Jun) $0.040 |
Volume (30-Jun) 696,012 |
Shortsold (26-May) 9,980 (0.00%) (676th) |
|
52w High $0.072 |
52w Low $0.019 |
P/E 25.97 |
EPS -0.01 |
ACW released this announcement to the ASX on 22 December 2022, 12:01. The announcement is marked as price sensitive, and is 2 page(s) in length and 235.52kb in size.
You can view all announcements from ACW and see how they appear on a price chart on the announcements page.
At the date of this announcement, ACW was 0.075% short sold according to ASIC data. It was ranked the 469th most shorted stock on the ASX. It remains ranked 676th as of the latest reported data (26 May 2026).
| Other Recent Announcements from ACW | |
|---|---|
| ACW CEO presentation on emerging oral Alzheimers therapies | 21 June 2023, 8:50 |
| ACW CEO & CMO present at BIO International Convention | 5 June 2023, 9:06 |
| ACW AD trial amendment and Clinical Science Forum slides | 24 May 2023, 8:20 |
| FDA agrees to six-month Phase 2b Alzheimers Disease Trial | 22 December 2022, 12:01 |
| Cleansing Notice | 9 December 2022, 10:48 |
| Application for quotation of securities - ACW | 9 December 2022, 10:45 |
| First patient treated in XanaCIDD Phase 2 Depression Trial | 8 December 2022, 13:29 |
You must be logged in to post a reply.
Actinogen Medical 